Maurilio Ponzoni

List of Publications by Year
in descending order

43 papers	4,124 citations	236925 25 h-index	315739 38 g-index
43 all docs	43 docs citations	43 times ranked	6602 citing authors

#	Article	IF	Citations
1	Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells. Nature Medicine, 2018, 24, 739-748.	30.7	947
2	MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program. Blood, 2013, 121, 4021-4031.	1.4	596
3	Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial. Lancet Haematology,the, 2016, 3, e217-e227.	4.6	442
4	Mutational profile and prognostic significance of TP53 in diffuse large B-cell lymphoma patients treated with R-CHOP: report from an International DLBCL Rituximab-CHOP Consortium Program Study. Blood, 2012, 120, 3986-3996.	1.4	301
5	Whole-brain radiotherapy or autologous stem-cell transplantation as consolidation strategies after high-dose methotrexate-based chemoimmunotherapy in patients with primary CNS lymphoma: results of the second randomisation of the International Extranodal Lymphoma Study Group-32 phase 2 trial. Lancet Haematology,the, 2017, 4, e510-e523.	4.6	258
6	Intravascular large B-cell lymphoma: a chameleon with multiple faces and many masks. Blood, 2018, 132, 1561-1567.	1.4	161
7	Final Results of the IELSG-19 Randomized Trial of Mucosa-Associated Lymphoid Tissue Lymphoma: Improved Event-Free and Progression-Free Survival With Rituximab Plus Chlorambucil Versus Either Chlorambucil or Rituximab Monotherapy. Journal of Clinical Oncology, 2017, 35, 1905-1912.	1.6	143
8	Rearrangements of MYC gene facilitate risk stratification in diffuse large B-cell lymphoma patients treated with rituximab-CHOP. Modern Pathology, 2014, 27, 958-971.	5.5	112
9	Immune Profiling and Quantitative Analysis Decipher the Clinical Role of Immune-Checkpoint Expression in the Tumor Immune Microenvironment of DLBCL. Cancer Immunology Research, 2019, 7, 644-657.	3.4	106
10	Risk‐tailored <scp>CNS</scp> prophylaxis in a mono‐institutional series of 200 patients with diffuse large B‐cell lymphoma treated in the rituximab era. British Journal of Haematology, 2015, 168, 654-662.	2.5	90
11	Targeting Macrophages Sensitizes Chronic Lymphocytic Leukemia to Apoptosis and Inhibits Disease Progression. Cell Reports, 2016, 14, 1748-1760.	6.4	90
12	B lymphocytes directly contribute to tissue fibrosis in patients with IgG4-related disease. Journal of Allergy and Clinical Immunology, 2020, 145, 968-981.e14.	2.9	85
13	Lectin binding to surface Ig variable regions provides a universal persistent activating signal for follicular lymphoma cells. Blood, 2015, 126, 1902-1910.	1.4	79
14	Bone marrow endothelial cells sustain a tumor-specific CD8^{+} T cell subset with suppressive function in myeloma patients. OncoImmunology, 2019, 8, e1486949.	4.6	58
15	MYD88 L265P MUTATION DETECTION IN THE AQUEOUS HUMOR OF PATIENTS WITH VITREORETINAL LYMPHOMA. Retina, 2019, 39, 679-684.	1.7	50
16	Excessive antigen reactivity may underlie the clinical aggressiveness of chronic lymphocytic leukemia stereotyped subset #8. Blood, 2015, 125, 3580-3587.	1.4	49
17	Clinical features, tumor biology, and prognosis associated with MYC rearrangement and Myc overexpression in diffuse large B-cell lymphoma patients treated with rituximab-CHOP. Modern Pathology, 2015, 28, 1555-1573.	5.5	48
18	Long-term efficacy, safety and neurotolerability of MATRix regimen followed by autologous transplant in primary CNS lymphoma: 7-year results of the IELSG32 randomized trial. Leukemia, 2022, 36, 1870-1878.	7.2	47

#	Article	IF	Citations
19	MDM2 phenotypic and genotypic profiling, respective to TP53 genetic status, in diffuse large B-cell lymphoma patients treated with rituximab-CHOP immunochemotherapy: a report from the International DLBCL Rituximab-CHOP Consortium Program. Blood, 2013, 122, 2630-2640.	1.4	46
20	<i>MYD88</i> L265P mutation and interleukin‐10 detection in cerebrospinal fluid are highly specific discriminating markers in patients with primary central nervous system lymphoma: results from a prospective study. British Journal of Haematology, 2021, 193, 497-505.	2.5	41
21	Synergistic Leukemia Eradication by Combined Treatment with Retinoic Acid and HIF Inhibition by EZN-2208 (PEG-SN38) in Preclinical Models of PML-RARα and PLZF-RARα–Driven Leukemia. Clinical Cancer Research, 2015, 21, 3685-3694.	7.0	40
22	AKT Hyperactivation and the Potential of AKT-Targeted Therapy in Diffuse Large B-Cell Lymphoma. American Journal of Pathology, 2017, 187, 1700-1716.	3.8	39
23	Cellular Senescence Markers p16INK4a and p21CIP1/WAF Are Predictors of Hodgkin Lymphoma Outcome. Clinical Cancer Research, 2015, 21, 5164-5172.	7.0	33
24	Marginal zone B-cell lymphoma: lessons from Western and Eastern diagnostic approaches. Pathology, 2020, 52, 15-29.	0.6	33
25	Lenalidomide maintenance in patients with relapsed diffuse large B-cell lymphoma who are not eligible for autologous stem cell transplantation: an open label, single-arm, multicentre phase 2 trial. Lancet Haematology,the, 2017, 4, e137-e146.	4.6	28
26	A Spatially Resolved Dark- versus Light-Zone Microenvironment Signature Subdivides Germinal Center-Related Aggressive B Cell Lymphomas. IScience, 2020, 23, 101562.	4.1	27
27	Clarithromycin as a "repurposing drug" against MALT lymphoma. British Journal of Haematology, 2018, 182, 913-915.	2.5	23
28	A refined cell-of-origin classifier with targeted NGS and artificial intelligence shows robust predictive value in DLBCL. Blood Advances, 2020, 4, 3391-3404.	5.2	22
29	Genetic Subtyping and Phenotypic Characterization of the Immune Microenvironment and MYC/BCL2 Double Expression Reveal Heterogeneity in Diffuse Large B-cell Lymphoma. Clinical Cancer Research, 2022, 28, 972-983.	7.0	22
30	Intra-tumour heterogeneity of diffuse large B-cell lymphoma involves the induction of diversified stroma-tumour interfaces. EBioMedicine, 2020, 61, 103055.	6.1	21
31	Aggressive B-cell Lymphoma with MYC/TP53 Dual Alterations Displays Distinct Clinicopathobiological Features and Response to Novel Targeted Agents. Molecular Cancer Research, 2021, 19, 249-260.	3.4	20
32	Toll-like receptor stimulation in splenic marginal zone lymphoma can modulate cell signaling, activation and proliferation. Haematologica, 2015, 100, 1460-1468.	3.5	19
33	Cutaneous localization in multiple myeloma in the context of bortezomib-based treatment: how do myeloma cells escape from the bone marrow to the skin?. International Journal of Hematology, 2017, 105, 104-108.	1.6	14
34	Inhibition of chronic lymphocytic leukemia progression by full-length chromogranin A and its N-terminal fragment in mouse models. Oncotarget, 0, 7, 41725-41736.	1.8	9
35	Follicular helper T cell signature of replicative exhaustion, apoptosis, and senescence in common variable immunodeficiency. European Journal of Immunology, 2022, 52, 1171-1189.	2.9	9
36	Genomic complexity is associated with epigenetic regulator mutations and poor prognosis in diffuse large B-cell lymphoma. OncoImmunology, 2021, 10, 1928365.	4.6	6

#	Article	IF	Citations
37	A Bitter Effect: Thrombocytopenia Induced by a Quinidine-containing Beverage. American Journal of Medicine, 2014, 127, e1-e2.	1.5	4
38	Treating life-threatening TAFRO syndrome with interleukin-1 inhibition. European Journal of Internal Medicine, 2021, 87, 121-123.	2.2	3
39	Off-Tumor Target Expression Levels Do Not Predict CAR-T Cell Killing: A Foundation For The Safety Of CD44v6-Targeted T Cells. Blood, 2013, 122, 142-142.	1.4	2
40	Implications of recent molecular achievements in early diagnosis and precision treatments for primary CNS lymphoma. Expert Opinion on Therapeutic Targets, 2021, 25, 749-760.	3.4	1
41	Modeling the Genotoxicity of Viral Vector Integration in a Tumor Prone Hematopoietic Stem Cell Transplantation Model.. Blood, 2006, 108, 451-451.	1.4	0
42	Risk-Tailored CNS Prophylaxis In 194 Patients With Diffuse Large B-CELL Lymphoma (DLBCL) Treated In The Rituximab ERA: Risk Definition By Clinical Variables and Ontogenic Stratification. Blood, 2013, 122, 4365-4365.	1.4	0
43	Myc and the Warburg Effect. Blood, 2018, 132, SCI-12-SCI-12.	1.4	0